{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:53:36Z","timestamp":1761807216794,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":3060,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s13311-015-0349-7","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T09:21:00Z","timestamp":1426843260000},"page":"287-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Spectrum of Motor Neuron Diseases: From Childhood Spinal Muscular Atrophy to Adult Amyotrophic Lateral Sclerosis"],"prefix":"10.1016","volume":"12","author":[{"given":"Stacey A.","family":"Sakowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0349-7_bib1","doi-asserted-by":"crossref","unstructured":"Farrar M, Kiernan M. The genetics of spinal muscular atrophy: progress and challenges. Neurother 2015. 10.1007\/s13311-014-0314-x (in this issue).","DOI":"10.1007\/s13311-014-0314-x"},{"key":"10.1007\/s13311-015-0349-7_bib2","doi-asserted-by":"crossref","unstructured":"d'Ydewalle C, Sumner C. Spinal muscular atrophy therapeutics: Where do we stand? Neurother 2015. 10.1007\/s13311-015-0337-y (in this issue).","DOI":"10.1007\/s13311-015-0337-y"},{"key":"10.1007\/s13311-015-0349-7_bib3","doi-asserted-by":"crossref","unstructured":"Rosenfeld J, Strong M. Challenges in the understanding and treatment of amyotrophic lateral sclerosis\/motor neuron disease. Neurother 2015. 10.1007\/s13311-014-0332-8 (in this issue).","DOI":"10.1007\/s13311-014-0332-8"},{"key":"10.1007\/s13311-015-0349-7_bib4","doi-asserted-by":"crossref","unstructured":"Cooper-Knock J, Kirby J, Highley R, Shaw PJ. The spectrum of C9orf72-mediated neurodegeneration and amyotrophic lateral sclerosis. Neurother 2015. 10.1007\/s13311-015-0342-1 (in this issue).","DOI":"10.1007\/s13311-015-0342-1"},{"key":"10.1007\/s13311-015-0349-7_bib5","doi-asserted-by":"crossref","unstructured":"Barmada S. Linking RNA dysfunction and neurodegeneration in amyotrophic lateral sclerosis. Neurother 2015. 10.1007\/s13311-015-0340-3 (in this issue).","DOI":"10.1007\/s13311-015-0340-3"},{"key":"10.1007\/s13311-015-0349-7_bib6","doi-asserted-by":"crossref","unstructured":"Scotter E, Chen H-J, Shaw C. TDP-43 proteinopathy and ALS: Insights into disease mechanism and therapeutic targets. Neurother 2015. 10.1007\/s13311-015-0338-x (in this issue).","DOI":"10.1007\/s13311-015-0338-x"},{"key":"10.1007\/s13311-015-0349-7_bib7","doi-asserted-by":"crossref","unstructured":"Hooten KG, Beers D, Zhou W, Appel S. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurother 2015. 10.1007\/s13311-014-0329-3 (in this issue).","DOI":"10.1007\/s13311-014-0329-3"},{"key":"10.1007\/s13311-015-0349-7_bib8","doi-asserted-by":"crossref","unstructured":"Nicholson K, Cudkowicz M, Berry J. Clinical trial designs in amyotrophic lateral sclerosis: Does one design fit all? Neurother 2015. 10.1007\/s13311-015-0341-2 (in this issue).","DOI":"10.1007\/s13311-015-0341-2"},{"key":"10.1007\/s13311-015-0349-7_bib9","doi-asserted-by":"crossref","unstructured":"Rutkove S. Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurother 2015. 10.1007\/s13311-014-0331-9 (in this issue).","DOI":"10.1007\/s13311-014-0331-9"},{"key":"10.1007\/s13311-015-0349-7_bib10","doi-asserted-by":"crossref","unstructured":"Simmons Z. Patient-perceived outcomes and quality of life in ALS. Neurother 2015. 10.1007\/s13311-014-0322-x (in this issue).","DOI":"10.1007\/s13311-014-0322-x"},{"key":"10.1007\/s13311-015-0349-7_bib11","doi-asserted-by":"crossref","unstructured":"Verstraete E, Foerster B. Neuroimaging as a new diagnostic modality in amyotrophic lateral sclerosis. Neurother 2015. 10.1007\/s13311-015-0347-9 (in this issue).","DOI":"10.1007\/s13311-015-0347-9"},{"key":"10.1007\/s13311-015-0349-7_bib12","doi-asserted-by":"crossref","unstructured":"Zach N, Ennist DL, Taylor AA, et al. Being PRO-ACTive: What can a clinical trial database reveal about ALS? Neurother 2015. 10.1007\/s13311-015-0336-z (in this issue).","DOI":"10.1007\/s13311-015-0336-z"},{"key":"10.1007\/s13311-015-0349-7_bib13","unstructured":"Reddy L, Miller T. RNA-targeted therapeutics for amyotrophic lateral sclerosis. Neurother 2015. 10.1007\/s13311-015-0344-z (in this issue)."},{"key":"10.1007\/s13311-015-0349-7_bib14","doi-asserted-by":"crossref","unstructured":"Goutman SA, Chen KS, Feldman EL. Recent advances and the future of stem cell therapies in amyotrophic lateral sclerosis. Neurother 2015. 10.1007\/s13311-015-0339-9 (in this issue).","DOI":"10.1007\/s13311-015-0339-9"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0349-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0349-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:43:48Z","timestamp":1761806628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923008243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1878747923008243"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0349-7","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Spectrum of Motor Neuron Diseases: From Childhood Spinal Muscular Atrophy to Adult Amyotrophic Lateral Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0349-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}